Quickly approve the use of Ibrutinib (Imbruvica, Pharmacyclics and Janssen) to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) which has been proven in studies to work and experts have described as a " turning point" in the treatment of CLL.
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
